Inactive Ingredient Search for Approved Drug Products

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with G

Quarter Inactive Ingredient Route of Administration Dosage Form Maximum Potency per unit dose Maximum Daily Exposure Status
3099 Q3 2021 GLYCERIN TOPICAL CLOTH 50.00 mg Correction
3099 Q4 2021 GLYCERIN TOPICAL CLOTH 0.05 mg/mg Correction
3082 Q3 2021 GLYCERIN ORAL SUSPENSION 23520.00 mg MDE Replacement
3082 Q4 2021 GLYCERIN ORAL SUSPENSION 26208 mg MDE Replacement
3128 Q3 2021 GLYCERYL DIBEHENATE ORAL POWDER, FOR SOLUTION 2.00 mg MDE Replacement
3128 Q4 2021 GLYCERYL DIBEHENATE ORAL POWDER, FOR SOLUTION 2 mg MDE Replacement
3158 Q3 2021 GLYCERYL MONO AND DIPALMITOSTEARATE VAGINAL CREAM 4.00 %w/w MDE Replacement
3158 Q4 2021 GLYCERYL MONO AND DIPALMITOSTEARATE VAGINAL CREAM 160 mg MDE Replacement
3162 Q3 2021 GLYCERYL MONOCAPRYLOCAPRATE ORAL CAPSULE 374.24 mg MDE Replacement
3162 Q4 2021 GLYCERYL MONOCAPRYLOCAPRATE ORAL CAPSULE 501.9 mg MDE Replacement
3256 Q3 2021 GUAR GUM ORAL TABLET, CHEWABLE, EXTENDED RELEASE 24.00 mg MDE Replacement
3256 Q4 2021 GUAR GUM ORAL TABLET, CHEWABLE, EXTENDED RELEASE 36 mg MDE Replacement

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: September 30, 2021
Database Last Updated: October 21, 2021

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English